Prognostic role of Lipoprotein(a) in atherosc - EurekAlert
Findings from a phase 1 trial show that a single dose of an experimental therapy produced greater than 94% reductions in blood levels of lipoprotein(a), a key driver of heart disease risk, with the results lasting for nearly a year
